Cargando…
Use of Social Media Tools during COVID-19 Pandemic Among MS Fellowships and Patients
BACKGROUND: There was no evidence about how COVID-19 can affect the neuroimmunological situation in patients who use immunosuppressive or immunomodulatory medications at the beginning of the COVID-19 pandemic in June 2020. Many concerns have arisen among clinicians regarding the management of Multip...
Autores principales: | Mokhberdezfuli, Mahdieh, Sahrian, Mohammad Ali, Moghadasi, Abdorreza Naser |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Published by Elsevier B.V.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10065166/ http://dx.doi.org/10.1016/j.msard.2022.104299 |
Ejemplares similares
-
Is Body Mass Index (BMI) Associated with Risk and Outcomes of COVID-19 in Iranian Multiple Sclerosis Patients?
por: Rezaeimanesh, Nasim, et al.
Publicado: (2023) -
Role of Type 1 Interferons therapy on Adverse Clinical Outcomes on COVID-19 in Hospitalized Multiple Sclerosis Patients
por: Maghbooli, Zhila, et al.
Publicado: (2023) -
Low-Dose Whole Thorax Radiation Therapy for COVID-19 Pneumonia: Inpatient Onboarding Process for a Randomized Controlled Trial
por: McClelland III, S., et al.
Publicado: (2021) -
Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of COVID-19 in Multiple Sclerosis: A MENACTRIMS Registry Based Study
por: Zeineddine, Maya, et al.
Publicado: (2023) -
Tixagevimab and Cilgavimab (Evusheld) Boosts Antibody Levels to SARS-Cov-2 in Patients with Multiple Sclerosis on B-Cell Depleters
por: Conte, William L., et al.
Publicado: (2023)